alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# CE2004078EN.01093001.xml

| 27.3.2004 | EN | Official Journal of the European Union | CE 78/930 |
| --- | --- | --- | --- |

27.3.2004

EN

Official Journal of the European Union

CE 78/930

---

(2004/C 78 E/0984)

WRITTEN QUESTION E-0095/04

by Mihail Papayannakis (GUE/NGL) to the Commission

(21 January 2004)

Subject:   Public hospital INMI L. Spallanzani in Italy

Subject:

According to reports in the Italian press, the ultra-modern public hospital in Rome, INMI L. Spallanzani, which specialises in infectious diseases, is gradually being converted into a ‘national security’ medical establishment. This means that it will be equipped — if it has not been already — with maximum security laboratories for combating level 4 bacteria and viruses (Ebola, bacillus etc.).

As the hospital is located in one of the most densely populated areas of Rome, will the Commission say whether the hospital has obtained the necessary certification to operate from international and European organisations, particularly in regard to storing level 4 pathogenic bacteria and viruses? Does the Commission know whether an agreement has been signed between Italy and the USA to combat biological terrorism?

Answer given by Mr Byrne on behalf of the Commission

(23 February 2004)

(23 February 2004)

Authorisation of hospitals and of their laboratories and any associated certification are matters for the Member States.

There are no requirements for authorisation or notification at European level on this matter; however Bio-Security Level 4 structures usually seek international certification.

A framework agreement concerning co-operation in research between Italy and the United States has been signed and ratified by ordinance DL/22 in January 2004. This framework agreement includes three fields: rare diseases, cancer and bio terrorism.

---
Exhibit 31.2

 

 

CERTIFICATION

I, Thomas J. Weldgen, Chief Financial Officer of CPAC, Inc., certify that:
1.
I have reviewed this quarterly report on Form 10-Q of CPAC, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
[Reserved] [Paragraph omitted pursuant to SEC Release Nos. 33-8392 and 34-49313.]
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:  February 13, 2007
REF ID:A63253 

Mr. John c. )kAleraoa •1• Pro•idoni 

%11'9rua.t1o=al llu.11.Ma• JIHhf.nu Corg. "9 111419011 A'ff.OUlt 

In' fork 12, RIV fork 

DlaJo lobn1 

IA ~~'IJ Vltb cw- dUcn.uletona oa l' Mrua.ry 

1'55, X ~ 9'ht letter• to .cm Gt\» >oard ~ra. 

% ua iaalo•S.. 'tilO ·~·• tor JOUr Wcmat1C111. 

I• looldnc tonaN to ... iaa JCIU ... 10 ill A,pr-11. 

Inetl.11 

a/• 

CCI NJ 

~:~'f*"" • .....s ISAR Mr. Wi1dom} 

tinoerol.J', 

K/Rs All Cbair.oo.n ot 1'SASAB, Mr. Mc:Pberaou diacuuted Yit.h Mr. Friedman,, 

O.neral Ce.nim am. Mr. Clark on 15 Feb 55 the plan.a terr & tvo .. &q e•sion o.t ISABAB .. 

@'pp roved for Release by NSA on 06-19-2014 pursuantto E .0. 1352a 

;;: 

" ' 

-

t 

•
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          OCT-31-1998
<PERIOD-START>                             NOV-01-1998
<PERIOD-END>                               APR-30-1999
<CASH>                                          24,196
<SECURITIES>                                         0
<RECEIVABLES>                                   33,859
<ALLOWANCES>                                       635
<INVENTORY>                                     20,834
<CURRENT-ASSETS>                                80,030
<PP&E>                                          10,136
<DEPRECIATION>                                   3,212
<TOTAL-ASSETS>                                  91,238
<CURRENT-LIABILITIES>                            5,939
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            88
<OTHER-SE>                                      83,771
<TOTAL-LIABILITY-AND-EQUITY>                    91,238
<SALES>                                         75,153
<TOTAL-REVENUES>                                75,153
<CGS>                                           52,169
<TOTAL-COSTS>                                   52,169
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                    54
<INTEREST-EXPENSE>                                  13
<INCOME-PRETAX>                                  7,510
<INCOME-TAX>                                     3,003
<INCOME-CONTINUING>                              4,507
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,507
<EPS-BASIC>                                      .51
<EPS-DILUTED>                                      .47


</TABLE>
### ATTACHMENT C

Letter dated April 27, 2007, submitted by Chemstone

in support of its BART determination
<PAGE>
 
                                                                       Exhibit 5

                           [ROPES & GRAY LETTERHEAD]



                                                                  April 29, 1999


Summit Technology, Inc.
21 Hickory Drive
Waltham, MA 02154

     Re:  Summit Technology, Inc.
          -----------------------

Ladies and Gentlemen:

     This opinion is furnished to you in connection with a registration
statement on Form S-8 (the "Registration Statement"), to be filed with the
Securities and Exchange Commission under the Securities Act of 1933, as amended,
for the registration of 868,689 shares of Common Stock, $0.01 par value (the
"Shares"), of Summit Technology, Inc., a Massachusetts corporation (the
"Company").

     We have acted as counsel for the Company and are familiar with the actions
taken by the Company in connection with the Autonomous Technologies Corporation
1995 Stock Option Plan (the "Plan").  For purposes of this opinion we have
examined the Plan and such other documents, records, certificates and other
instruments as we have deemed necessary.

     We express no opinion as to the applicability of compliance with or effect
of federal law or the law of any jurisdiction other than The Commonwealth of
Massachusetts.

     Based on the foregoing, we are of the opinion that the Shares have been
duly authorized and, when the Shares have been issued and sold and consideration
received therefor by the Company in accordance with the terms of the Plan, the
Shares will be validly issued, fully paid and non-assessable.

     We hereby consent to your filing this opinion as an exhibit to the
Registration Statement.

     It is understood that this opinion is to be used only in connection with
the offer and sale of the Shares while the Registration Statement is in effect.

                              Very truly yours,

                              /s/ Ropes & Gray

                              Ropes & Gray
COURT OF APPEALS OF VIRGINIA 

Present: Judges Beales, Russell and Senior Judge Frank 

ZAINAB T. AHMED 

 MEMORANDUM OPINION*

v. Record No. 1851-14-4 PER CURIAM 

 JUNE 9, 2015 

TRINET/WASHINGTON DULLES MARRIOTT AND 

 INSURANCE COMPANY OF THE STATE OF PENNSYLVANIA 

 FROM THE VIRGINIA WORKERS’ COMPENSATION COMMISSION 

 (Zainab T. Ahmed, pro se, on brief). 

 (Andrew E. Suddarth; Jordan Coyne LLP, on brief), for appellees. 

 Zainab T. Ahmed appeals a decision of the Workers’ Compensation Commission finding 

that several physical ailments were not causally related to her work injury and that 

Trinet/Washington Dulles Marriott and the insurance company were not responsible for payment 

of emergency room visits, a neck collar, and treatment for the several conditions. Appellant also 

filed motions for the appointment of counsel and for the Court to impose fines against appellees’ 

counsel. Appellees filed a motion to dismiss appellant’s appeal for failure to comply with Rules 

5A:20, 5A:25, and 5A:26. 

 We have reviewed the record and the commission’s opinion and find that this appeal is 

without merit. Accordingly, we affirm for the reasons stated by the commission in its final 

opinion. See Ahmed v. Trinet/Washington Dulles Marriott, VWC File No. VA00000327899 

(Sept. 16, 2014). We dispense with oral argument and summarily affirm because the facts and 

legal contentions are adequately presented in the materials before the Court and argument would 

 *

 Pursuant to Code § 17.1-413, this opinion is not designated for publication. 

UNPUBLISHED 
 - 2- 

not aid the decisional process. See Code § 17.1-403; Rule 5A:27. We deny appellant’s motions 

for appointed counsel and to impose fines against appellees’ counsel and appellees’ motion to 

dismiss with prejudice. 

 Affirmed.
# Official Journal L 295/2011

| | ISSN 1977-0677
  doi:10.3000/19770677.L_2011.295.eng |
| --- | --- |
| Official Journal
  of the European Union | L 295 |
| | |
| English edition | Legislation | Volume 5412 November 2011 |

ISSN 1977-0677

doi:10.3000/19770677.L_2011.295.eng

Official Journal

of the European Union

L 295

English edition

Legislation

Volume 5412 November 2011

---

| Contents | | II   Non-legislative acts | page |
| --- | --- | --- | --- |
| | | REGULATIONS |
| | * | Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council by establishing a Union list of food additives (1) | 1 |
| | * | Commission Regulation (EU) No 1130/2011 of 11 November 2011 amending Annex III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives by establishing a Union list of food additives approved for use in food additives, food enzymes, food flavourings and nutrients (1) | 178 |
| | * | Commission Regulation (EU) No 1131/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council with regard to steviol glycosides (1) | 205 |

Contents

II   Non-legislative acts

page

REGULATIONS

*

Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council by establishing a Union list of food additives (1)

1

*

Commission Regulation (EU) No 1130/2011 of 11 November 2011 amending Annex III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives by establishing a Union list of food additives approved for use in food additives, food enzymes, food flavourings and nutrients (1)

178

*

Commission Regulation (EU) No 1131/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council with regard to steviol glycosides (1)

205

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.
  The titles of all other Acts are printed in bold type and preceded by an asterisk. |
| --- | --- |

EN

Acts whose titles are printed in light type are those relating to day-to-day management of agricultural matters, and are generally valid for a limited period.

The titles of all other Acts are printed in bold type and preceded by an asterisk.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                              14
<SECURITIES>                                         0
<RECEIVABLES>                                    1,016
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 1,121
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                   2,290
<CURRENT-LIABILITIES>                              812
<BONDS>                                            800
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            38
<OTHER-SE>                                     (1,355)
<TOTAL-LIABILITY-AND-EQUITY>                     2,290
<SALES>                                            179
<TOTAL-REVENUES>                                   179
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                   184
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 190
<INCOME-PRETAX>                                  (278)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (278)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (278)
<EPS-BASIC>                                      (.10)
<EPS-DILUTED>                                        0


</TABLE>
Order entered March 4 , 2015

In The 

## Court of Appeals **Fifth District of Texas at Dallas**
No. 05
- 14
- 01269
- CV
IN RE HERMES SARGENT BATES , LLP AND COLLEEN MC COY, Relator Original Proceeding from the 44th Judicial District Court Dallas County, Texas Trial Court Cause No. 12
- 03421 

### O RDER Before Justices Francis, Evans and Whitehill By order dated December 30, 2014, the Court abated the petition for writ of mandamus pursuant to rule 7.2(b) of the Texas Rules of Appellate Procedure to allow the successor judg e to reconsider the trial court’s ruling. Relator moves to dismiss the petition for writ of mandamus stating the trial court has granted relator’s motion for reconsideration and has granted the relief sought by the petition for wr it of mandamus . We ORDER the petition for writ of mandamus REINSTATED . We LIFT the stay of proceedings in the trial court imposed by this Court’s October 8, 2014 order . We GRANT relator’s motion to dismiss the petition for writ of mandamus. Pursuant to the Court’s opinion of t his date, we DISMISS the petition for writ of mandamus. We ORDER the parties to bear their own costs o f this original proceeding.

/s/ DAVID EVANS JUSTICE
This memorandum opinion was not selected for publication in the New Mexico Reports. Please 1 see Rule 12-405 NMRA for restrictions on the citation of unpublished memorandum opinions. 2 Please also note that this electronic memorandum opinion may contain computer-generated 3 errors or other deviations from the official paper version filed by the Court of Appeals and does 4 not include the filing date. 5 IN THE COURT OF APPEALS OF THE STATE OF NEW MEXICO 6 JOE LOPEZ, JR, 7 Worker-Appellant, 8
v. NO. 31,189 9 YELLOW FREIGHT, a/k/a YRC, INC., 10 and GALLAGHER BASSET SERVICES, 11 Employer/Insurer-Appellees. 12 APPEAL FROM THE WORKERS’ COMPENSATION ADMINISTRATION 13 Gregory D. Griego, Judge 14 Jeffrey C. Brown 15 Albuquerque, NM 16 for Appellant 17 Robert Bruce Collins 18 Albuquerque, NM 19 for Appellees 20 MEMORANDUM OPINION 21 VANZI, Judge. 222 Summary reversal was proposed for the reasons stated in the notice of proposed 1 summary disposition. No memorandum oppos ing summary reversal has been filed 2 and the time for doing so has expired. 3 REVERSED . 4 IT IS SO ORDERED. 5

__________________________________ 6 LINDA M. VANZI, Judge 7 WE CONCUR: 8

_________________________________ 9 CELIA FOY CASTILLO, Chief Judge 10

_________________________________ 11 JAMES J. WECHSLER, Judge 12
<PAGE>
                                                                               .
                                                                               .
                                                                               .

                                                                      EXHIBIT 21

                         SUBSIDIARIES OF THE REGISTRANT

<TABLE>
<CAPTION>
        SUBSIDIARY NAME                 STATE OF INCORPORATION  % OWNED
        ---------------                 ----------------------  -------
<S>                                     <C>                     <C>
Associated Pharmacies, Inc. (inactive)       Arkansas             100%

VC Services, Inc.                            Minnesota            100%

Pharmaceutical Buyers, Inc.                  Arkansas              70%

Jaron, Inc.                                  Florida              100%

D & K Receivables Corporation                Delaware             100%

Jewett Drug Co.                              South Dakota         100%

Tykon, Inc.                                  Wisconsin            100%

Southwest Computer Systems, Inc.             Arkansas             100%
         (inactive)

U.P.C., Inc. (inactive)                      Minnesota            100%

Diversified Healthcare, LLC                  Kentucky             100%

Medical & Vaccine Products, Inc.             Puerto Rico          100%

D&K Pharmacy Solutions, Inc.                 Delaware             100%

Walsh Heartland, L.L.C.                      Arkansas             100%

Walsh Distribution L.L.C.                    Arkansas             100%

Walsh Healthcare Solutions, Inc.             Arkansas             100%

Myhca, Inc.                                  Texas                100%

Healthcare Alliance LLC                      Alabama               50%
</TABLE>
**Exhibit 32.1**

**Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

          Solely for the purpose of complying with 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, the undersigned Chief Executive Officer of Somanta Pharmaceuticals, Inc. (the “Company”), hereby certify, based on my knowledge, that the Annual Report on Form 10-KSB of the Company for the year ended April 30, 2007 (the “Report”) fully complies with the requirements of Section 13(a)  or 15(d) of the Securities and Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

| Date:    June 29, 2007 |                                  |
|-----------------------------|---------------------------------------|
|                        |                                  |
|                        |                                  |
| By:                         | /s/ Agamemnon A. Epenetos             |   |
|                        |                                       |   |
|                        | Agamemnon A. Epenetos                 |   |
|                        | President and Chief Executive Officer |   |